Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | NICE osimertinib rejection: UK patients

Tom Newsom-Davis • 31 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer Osimertinib

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, talks on the rejection of osimertinib by NICE and the impact this may have on UK treatment outcomes, specifically patients with EGFR-mutant non-small cell lung cancer (NSCLC). This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Tom Newsom-Davis

0:47
Novel insights from BTOG 2023
Tom Newsom-Davis • 3 May 2023
1:53
The role of NICE in the UK for lung cancer
Tom Newsom-Davis • 27 Apr 2023
1:57
BTOG 2021 highlights: immunotherapy for mesothelioma and cardiac toxicity updates
Tom Newsom-Davis • 23 Apr 2021
2:39
COVID-19 and the future of lung cancer treatment in the UK
Tom Newsom-Davis • 23 Apr 2021

Related Videos

3:35
Lung cancer initiation: towards molecular cancer prevention
Charles Swanton • 18 Apr 2024
0:37
STABLE-MATES: sublobar resection vs SAbR in high-risk patients with stage I NSCLC
Clive Peedell • 18 Apr 2024
0:44
BTOG 2024: networking highlights and insights
Clive Peedell • 18 Apr 2024
0:49
Ongoing trials in thoracic radiotherapy: evaluating current role and significance
Thomas Newsom-Davis • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals